Sandoz (SDZNY) announced that the European Commission, or EC, has granted marketing authorization for Afqlir 2 mg vial kit and pre-filled syringe for intravitreal injection, a biosimilar to reference medicine Eylea. Afqlir is indicated to treat various retinal diseases, including neovascular age-related macular degeneration, or nAMD, aiming to prevent disease-related blindness. Afqlir is one of several biosimilar value drivers for Sandoz and this approval represents a major step in advancing the company’s growth strategy. Launch is expected as of Q4 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SDZNY:
- Sandoz price target raised to CHF 36 from CHF 33 at Deutsche Bank
- Sandoz price target raised to CHF 39 from CHF 38 at Berenberg
- Sandoz price target raised to CHF 42 from CHF 40 at RBC Capital
- Sandoz price target raised to CHF 35 from CHF 32 at Morgan Stanley
- Sandoz price target raised to CHF 43 from CHF 36.50 at JPMorgan
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
